The General Hospital Corporation

Rhode Island Hospital

Massachusetts General Hospital Corporation

Other

Albert Einstein College of Medicine

Centocor, Inc.

Midwestern University

Rhode Island Hospital, a Lifespan-partner

Massachusetts Institute of Technology

Celgene Corporation

Brown University

The General Hospital Corpoation

Geistlich Pharma Ag

Panacea Pharmaceuticals, Inc.

Jack Raymond Wands

Suzanne M De La Monte

Rolf I Carlson

Vincent R Zurawski, Jr

Nedim Ince

Suzanne De La Monte

Takaji Wakita

Dominique Bellet

Tsanyang Jake Liang

Suzanne Marie De La Monte

Mehmet Ozturk

Hiroshi Takahashi

Catherine Julia Pachuk

Mark Jon Olsen

Hubert J Schoemaker

David A Shafritz

John-Michael Thomas

Leslie R Coney

Paul Maggio

Miran Kim

Arihiro Aihara

Shuping Tong

Jisu Li

K Dane Wittrup

Hossein A Ghanbari

Jerome Gross

Christoph Rose-Petruck

Alan H Deutch

Eithan Galun

Danielle Rand

Shinji Tanaka

Hubert E Blum

Barbara L Westrick

Schoemaker, Hubert J P

Darius Moradpour

Daniel Shouval

Takaja Wakita

Katsutoshi Tokushige

Margherita Melegari

Pier Paolo Scaglioni

Jens Encke

Robert W Esmond

Yik Andy Yeung

Philippe Merle

Sarah Beseme

Vivian Ortiz

Zoltan Derdak

Masafumi Shimoda

Suzanne De Lamonte

The present disclosure relates to antibodies that bind human chitinase-3-like protein 1 (CHI3L1) and uses thereof. In aspects, the antibodies are useful in compositions and methods for detecting and/or treating nonalcoholic steatohepatitis (NAFLD) or nonalcoholic fatty liver disease (NASH) in a subject, as well as subsequent complications of untreated progression in the liver of a subject, such as liver cirrhosis and/or a hepatocellular carcinoma.

Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fatty liver disease/nonalcoholic steatonhepatitis and subsequent complications

Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications

The present invention provides a peptide-based immunotherapy for ASPH-expressing tumors.

Aspartate-&#x3b2;-hydroxylase induces epitope-specific T cell responses in tumors

The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.

Inhibitors of &#x3b2;-hydroxylase for treatment of cancer

The specification provides compositions and methods of reducing a risk of a HBV infection in a subject and of treating a subject infected with HBV.

Treating hepatitis B virus infections by administering receptor associated protein (RAP)

The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydroxylase (e.g., Asparatyl (asparaginyl) &#x3b2;-hydroxylase (ASPH)), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.

Inhibitors of beta-hydroxylase for treatment of cancer

This invention relates to methods for treating, preventing, or reversing liver disease or damage produced by chronic alcohol intake by administering at least one peroxisome proliferator activated receptor (PPAR) agonist.

Treatment, prevention, and reversal of alcohol-induced liver disease

A vaccine containing AAH-loaded mature dendritic cells for treatment of AAH-expressing tumors in mammalian subjects. A method of producing primed dendritic cells is carried out by contacting isolated dendritic cells with an antigen such as AAH. Following the antigen-contacting step, the dendritic cells are contacted with a combination of cytokines such as GM-CSF and IFN-&#x3b3;.

Dendritic cell vaccines for asparaginyl-&#x3b2;-hydroxylase expressing tumors

Methods, compositions, systems, devices and kits are provided herein for preparing and using a nanoparticle composition and spatial frequency heterodyne imaging for visualizing cells or tissues. In various embodiments, the nanoparticle composition includes at least one of: a nanoparticle, a polymer layer, and a binding agent, such that the polymer layer coats the nanoparticle and is for example a polyethylene glycol, a polyelectrolyte, an anionic polymer, or a cationic polymer, and such that the binding agent that specifically binds the cells or the tissue. Methods, compositions, systems, devices and kits are provided for identifying potential therapeutic agents in a model using the nanoparticle composition and spatial frequency heterodyne imaging.

Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging

This invention relates to methods for treating, preventing, or reversing brain disease or damage produced by chronic alcohol intake by administering a peroxisome proliferator activated receptor (PPAR) agonist.

Treatment, prevention, and reversal of alcohol-induced brain disease

Provided herein are biomarkers for hepatocellular carcinoma and uses thereof.

Use of biomarkers in methods for the treatment of hepatocellular carcinoma

The present specification provides, inter alia, methods of using Wnt and FZD proteins, genes, FZD and Wnt-specific antibodies and probes in diagnosis and treatment of cancer and for screening test compounds for an ability to treat cancer. Also disclosed are compounds useful for treating cancer such as liver cancer.

Wnt proteins and detection and treatment of cancer

Frizzled proteins and detection and treatment of cancer

This invention relates to methods for diagnosing Alzheimer's Disease (AD) by determining the level or function of insulin, insulin-like growth factors, their receptors and/or their downstream signaling molecules. The invention further relates to methods for the treatment of AD by administering an insulin agonist and an insulin-like growth factor agonist. The invention additionally provides an animal model of AD and methods of screening for agents useful in the treatment, amelioration, or prevention of AD.

Treatment of Alzheimer's Disease

Antibodies, or antigen-binding portions thereof, to aspartyl (asparaginyl) &#x3b2;-hydroxylase are provided. The anti-aspartyl (asparaginyl) &#x3b2;-hydroxylase antibodies, or antigen-binding portions thereof, can modulate activity of aspartyl (asparaginyl) &#x3b2;-hydroxylase.

Anti-hydroxylase antibodies and uses thereof

Growing community of inventors

East Greenwich, RI, United States of America

Jack Raymond Wands